Clinical applications of next-generation sequencing in colorectal cancers

Table 3 The platforms used in the Cancer Genome Atlas consortium

Alteration types	Glioblastoma multiforme (2008, TCGA)	Colorectal cancers (2012, TCGA)
Point mutations, indels	Sanger sequencing	Illumina GA and HiSeq DNA Sequencing1
		ABI SOLiD DNA Sequencing1
DNA copy numbers	Agilent Human CGH Microarray 244 A	Agilent CGH Microarray Kit 1 × 1 M and 244 A
	Affymetrix Genome-Wide SNP Array 6.0	Affymetrix Genome-Wide SNP Array 6.0
	Illumina Human Infinium 550 K BeadChip	Illumina Infinium 550 K and 1M-Duo BeadChip
DNA Methylation	Illumina Infinium DNA Methylation 27	Illumina Infinium DNA Methylation 27
		Illumina DNA Methylation Cancer Panel I
Transcriptome	Affymetrix Human Genome U133 Plus 2.0	Illumina GA and HiSeq RNA sequencing1
	Agilent 244 K Custom Array	Agilent 244 K Custom Array
	Affymetrix Human Exon 1.0 ST Array
MicroRNA	Agilent 8 × 15 K Human miRNA Microarray	Illumina GA and HiSeq miRNA sequencing1
Whole-genome sequencing	N/A	Illumina HiSeq DNA sequencing1

¹Next-generation sequencing-based platforms are noted. The platforms used in the genomic characterization of glioblastoma multiforme in 2008 (left) and colorectal cancer genomes in 2012 (right) are shown. TCGA: The Cancer Genome Atlas.